AmplifyBio was honored as one of the most Innovative companies to watch in the Columbus area in 2022. We are honored to appear on a list of companies growing science and technology in the central Ohio region.
The event highlighted up-and-coming companies and entrepreneurs with Business First carrying on the long tradition of the former TechColumbus TopCat Awards and Innovation Awards with our BizTech Awards. The Honorees were celebrated with an in-person evening event at the Fawcett Event Center on the campus of Ohio State University.
Since its launch in 2021, AmplifyBio has added over 100 jobs to its West Jefferson campus and is leveraging decades of experience in creating complex systems in support of advanced therapies using a variety of modern clinical and commercial drug development solutions. Highlights from the first year include the opening of a state-of-the-art analytics lab, expansion with the addition of a discovery services site in South San Francisco, and the addition of partnerships and platforms to further the core mission of better characterizing innovative cell and gene therapies to advance safe, reproducible treatments for patients waiting for them.
The future is bright at AmplifyBio as we look toward opening a new 350,000-square-foot New Albany facility. With this investment, the company will undergo extensive hiring for research and development positions through 2023. AmplifyBio is expanding to meet significant unmet market demand, focusing on the characterization and safety of advanced therapies with services to complement the current safety, efficacy, and toxicology testing services.
In an interview conducted earlier this year J. Kelly Ganjei, AmplifyBio CEO said, “We are excited to expand our presence in the greater Columbus area, specifically New Albany. We believe the innovation platform we are bringing to the region is synergistic with and reflective of the collaborative environment that I first noticed when I came to Ohio. We are confident that our partners, collaborators, and clients see working in this region as an opportunity, and we are convinced that our business model will continue to drive more innovative developers into the area. We are eager to share more details about our development plans focused on ways to optimize advanced therapies soon, so stay tuned.”